Who makes ADA 0.1% gel?

ADA 0.1% gel is developed by GlaxoSmithKline.

What development phase is ADA 0.1% gel in?

ADA 0.1% gel is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

ADA 0.1% gel

GlaxoSmithKline · FDA-approved active Small molecule Quality 2/100

ADA 0.1% gel, marketed by GlaxoSmithKline, holds a position in the pharmaceutical market with its key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and revenue generation, though specific figures are not provided. The primary risk is the potential increase in competition post-patent expiry in 2028.

At a glance

Generic name	ADA 0.1% gel
Sponsor	GlaxoSmithKline
Modality	Small molecule
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

DUAC® Early Onset Efficacy Study in Japanese Subjects (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

ADA 0.1% gel CI brief — competitive landscape report
ADA 0.1% gel updates RSS · CI watch RSS
GlaxoSmithKline portfolio CI